Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioTime has amended its license from the University of Utah to extend the field of use for which it is licensed to manufacture and market products covered under HyStem technology patent.
Subscribe to our email newsletter
As part of the changed license, BioTime is now licensed globally for all uses, excluding veterinary medicine and animal health.
The extended field of use includes human pharmaceutical and medical device applications, tissue engineering and regenerative medicine uses and also research applications.
BioTime chief commercial officer William Tew said BioTime is pleased to have license to the full spectrum of human medical products possible with HyStem.
"In addition to Renevia™ which is currently in preclinical studies, we have initiated development programs for additional products that are planned as relatively near-term sources of revenue while strategically laying the foundation for the wide array of cell-based regenerative therapies that may be developed based on stem cell sciences," Tew added.